Registry of patients treated with heavy particle therapy for cancer
CNAO REgistry triAL - REGAL
CNAO National Center of Oncological Hadrontherapy · NCT05203250
This study is collecting information from cancer patients treated with advanced heavy particle therapy to see how well it works and what side effects it might cause.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3000 (estimated) |
| Sex | All |
| Sponsor | CNAO National Center of Oncological Hadrontherapy (other) |
| Drugs / interventions | radiation |
| Locations | 1 site (Pavia) |
| Trial ID | NCT05203250 on ClinicalTrials.gov |
What this trial studies
This registry collects both retrospective and prospective data from patients treated with particle therapy, specifically protons and carbon ions, at the National Center for Oncological Hadrontherapy in Pavia. The aim is to analyze and evaluate clinical outcomes and side effects associated with this advanced form of radiotherapy, which is particularly effective for tumors that are resistant to conventional treatments. By gathering comprehensive data on the natural history of cancer and treatment effects, the registry seeks to enhance understanding of the role of heavy particle therapy in oncology. This initiative will provide valuable insights for future clinical applications and improve patient care.
Who should consider this trial
Good fit: Ideal candidates include cancer patients who have been treated with heavy particles at the CNAO and can provide informed consent.
Not a fit: Patients who are unable to understand the informed consent document or have not received treatment with heavy particles will not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could lead to improved treatment protocols and outcomes for cancer patients receiving heavy particle therapy.
How similar studies have performed: Other studies on particle therapy have shown promising results, indicating that this approach is gaining recognition in the field of oncology.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients treated with heavy particles at Fondazione CNAO, Pavia * Patients who have the ability to understand and be willing to sign a written informed consent document Exclusion Criteria: * Patients or legal guardians who are unable to understand informed consent document
Where this trial is running
Pavia
- National Center for Oncological Hadrontherapy (CNAO) — Pavia, Italy (RECRUITING)
Study contacts
- Study coordinator: Chiara Campo, PhD
- Email: campo@cnao.it
- Phone: +39 0382078407
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer, Oncology, Radiation Exposure, Radiotherapy Side Effect, Radiation Toxicity, Rare Disease, Hadrontherapy, Radiotherapy